TABLE 2.
Gene | Drug | Therapy type | Connection with extracellular vesicles: Examples | References a |
---|---|---|---|---|
Genes with pharmacogenetic drug prescribing recommendations b | ||||
CYP2D6 | Tamoxifen | Hormone therapy | Protein detected in urine EVs (healthy donors, patients with nephropathy) | Moon et al. (2011) |
DPYD | Capecitabine, fluorouracil, tegafur | Chemotherapy | Protein detected in glioblastoma cells EVs and in urine EVs (healthy donors) | Fraser et al. (2013), Pavlyukov et al. (2018) |
TPMT | Mercaptopurine, thioguanine | Chemotherapy | Protein detected in various cancer cell line EVs and in urine EVs (healthy donors) | Hong et al. (2009), Wang et al. (2012), Bijnsdorp et al. (2013), Liang et al. (2013), Sinha et al. (2014), Liu et al. (2015), Hurwitz et al. (2016), Liem et al. (2017) |
mRNA detected in colorectal cancer cell EVs | ||||
UGT1A1 | Irinotecan | Chemotherapy | Protein detected in platelet EVs | Dean et al. (2009), Liu et al. (2020) |
mRNA detected in plasma derived EVs in lung adenocarcinoma | ||||
Genes with PharmGKB level 2A clinical annotations | ||||
ABCB1 | Methotrexate | Chemotherapy | Protein detected in various cancer cell line EVs, platelet EVs, serum EVs in prostate cancer and urine EVs (healthy donors) | Dean et al. (2009), Gonzales et al. (2009), Hong et al. (2009), Kato et al. (2015), Kharaziha et al. (2015), Hurwitz et al. (2016), Wang et al. (2019) |
mRNA detected in colorectal cancer cell EVs | ||||
NQ O 1 | Alkylating agents, anthracyclines and related substances, fluorouracil, platinum compounds | Chemotherapy | Protein detected in various cancer cell line EVs and in urine EVs (healthy donors) | Hong et al. (2009), Welton et al. (2010), Wang et al. (2012), Ji et al. (2013), Hurwitz et al. (2016), Liem et al. (2017), Choi et al. (2018) |
mRNA detected in colorectal cancer cell EVs | ||||
MTHFR | Carboplatin, cisplatin, methotrexate | Chemotherapy | Protein detected in various cancer cell line EVs | Hong et al. (2009), Hurwitz et al. (2016), Liem et al. (2017) |
mRNA detected in colorectal cancer cell EVs | ||||
GSTP1 | Fluorouracil, oxaliplatin, cyclophosphamide, epirubicin, platinum compounds | Chemotherapy | Protein detected in various cancer cell line EVs and in urine EVs (healthy donors, prostate cancer) | Skog et al. (2008), Gonzales et al. (2009), Hong et al. (2009), Welton et al. (2010), Fraser et al. (2013), Ji et al. (2013), Paggetti et al. (2015), Øverbye et al. (2015), Hurwitz et al. (2016), Yang S. et al. (2017), Lázaro-Ibáñez et al. (2017), Liem et al. (2017), Choi et al. (2018), Zhang et al. (2019) |
mRNA detected in colorectal cancer and glioblastoma cell EVs and serum derived EVs in breast cancer patients | ||||
SLCO1B1 | Methotrexate | Chemotherapy | Not reported | — |
TYMS | Capecitabine, fluorouracil | Chemotherapy | Protein detected in various cancer cell line EVs | Skog et al. (2008), Hong et al. (2009), Paggetti et al. (2015), Hurwitz et al. (2016), Liem et al. (2017), Choi et al. (2018) |
mRNA detected in colorectal cancer and glioblastoma cell EVs |
References from individual functional/biomarker EV studies and EV-omics studies from VesiclePedia or Exocarta.
Pharmacogenetic recommendations from CPIC or DPWG reported in PharmGKB, level 1A and 1B clinical annotations.